first
identifi
middl
east
respiratori
syndrom
mer
coronaviru
merscov
list
new
categori
c
prioriti
pathogen
high
mortal
merscov
infect
intensifi
potenti
humantohuman
transmiss
mer
vaccin
avail
human
use
review
explain
immun
respons
result
merscov
infect
describ
mer
vaccin
criteria
present
avail
small
anim
model
evalu
efficaci
mer
vaccin
current
advanc
vaccin
develop
summar
focus
specif
applic
limit
vaccin
categori
taken
togeth
review
provid
valuabl
guidelin
toward
develop
effect
safe
mer
vaccin
articl
written
special
focu
issu
expert
review
vaccin
vaccin
biodef
sinc
first
emerg
saudi
arabia
june
case
middl
east
respiratori
syndrom
mer
coronaviru
merscov
infect
report
countri
saudi
arabia
largest
number
mer
case
follow
south
korea
februari
mer
case
includ
death
case
fatal
rate
report
case
mer
keep
increas
saudi
arabia
reach
februari
similar
coronavirus
cov
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
porcin
epidem
diarrhea
viru
pedvcov
merscov
zoonot
viru
origin
bat
suggest
bat
like
natur
reservoir
merscov
howev
unlik
sarscov
util
small
anim
palm
civet
raccoon
dog
intermedi
host
merscov
depend
dromedari
camel
nevertheless
humantohuman
transmiss
merscov
occur
unprepar
healthcar
facil
could
becom
major
sourc
human
infect
transmiss
fig
shown
incid
merscov
case
south
korea
sever
famili
cluster
infect
merscov
also
reveal
recent
merscov
ad
niaid
list
categori
c
prioriti
pathogen
place
categori
sarscov
potenti
use
biolog
weapon
therefor
step
toward
prevent
strategi
need
taken
particularli
develop
effect
safe
vaccin
cov
genera
classifi
fig
cov
new
genu
coronavirida
famili
usual
infect
bird
includ
mammal
porcin
deltacoronaviru
new
strain
recent
identifi
us
caus
porcin
diarrhea
sever
cov
infect
human
merscov
sarscov
led
region
global
human
outbreak
although
merscov
sarscov
cov
interest
note
merscov
phylogenet
relat
batcov
fig
unlik
bind
bat
human
dipeptidyl
peptidas
receptor
merscov
directli
infect
bat
cell
indirectli
infect
number
human
cell
exogen
stimul
two
mutat
surfac
spike
protein
may
respons
transmit
merscov
bat
human
fig
thu
explain
origin
merscov
bat
similar
cov
merscov
genom
singl
positivestrand
rna
contain
two
larg
replicas
open
read
frame
orf
encod
two
proteas
papainlik
proteas
proteas
conserv
cov
downstream
merscov
genom
believ
encod
envelop
e
membran
nucleocapsid
n
structur
protein
respect
differ
function
fig
b
merscov
e
protein
exampl
promot
virul
surfac
protein
compos
subunit
respect
respons
cellular
receptor
bind
via
receptorbind
domain
rbd
fusion
viru
cell
membran
therebi
mediat
entri
merscov
target
cell
fig
merscov
rbd
consist
core
structur
homolog
sarscov
protein
rbd
receptorbind
motif
uniqu
merscov
thu
determin
viral
pathogenesi
receptor
recognit
addit
aforement
major
structur
protein
merscov
genom
also
encod
sever
accessori
protein
includ
howev
might
essenti
viru
replic
recent
studi
reveal
wholegenom
consensu
sequenc
merscov
dromedari
camel
human
ident
confirm
merscov
transmiss
dromedari
camel
human
merscov
infect
may
trigger
antigenspecif
humor
immun
respons
neutral
antibodi
camel
human
merscovor
sspecif
antibodi
includ
neutral
activ
identifi
dromedari
camel
mersaffect
region
includ
saudi
arabia
jordan
qatar
unit
arab
emir
addit
seropreval
merscovspecif
antibodi
shown
significantli
higher
individu
expos
camel
found
among
gener
popul
studi
merscovinfect
adult
patient
indic
surviv
serum
igg
neutral
antibodi
level
antibodi
weakli
invers
correl
viral
load
lower
respiratori
tract
south
korea
merscovinfect
human
also
demonstr
clear
kinet
serolog
respons
includ
robust
antibodi
respons
develop
earli
stage
diseas
onset
delay
antibodi
respons
neutral
activ
associ
later
sever
stage
diseas
studi
suggest
humor
immun
respons
includ
neutral
antibodi
play
import
role
prevent
merscov
infect
addit
b
cellmedi
antibodi
respons
cellular
immun
respons
mediat
specif
cell
may
play
supplementari
role
absenc
patient
die
merscov
infect
could
impair
product
antivir
adapt
immun
respons
suggest
might
import
induct
robust
cellular
immun
respons
initi
stage
diseas
progress
moreov
merscov
infect
may
drive
product
human
well
express
cytokin
chemokin
includ
rant
dendrit
cell
effect
modul
innat
immun
respons
mer
vaccin
also
induc
humor
cellular
immun
respons
specif
good
mer
vaccin
abl
induc
strong
humor
immun
respons
particularli
neutral
antibodi
vaccin
anim
human
complet
protect
immun
subject
merscov
challeng
depend
immun
rout
mer
vaccin
may
activ
b
cell
produc
system
igg
andor
secretori
iga
siga
antibodi
bind
viru
respect
mediat
system
mucos
immun
respons
serum
iga
could
also
induc
upon
vaccin
particularli
mucos
intranas
rout
antibodi
neutral
activ
neutral
merscov
infect
block
virustarget
cell
bind
via
cellular
receptor
thu
inhibit
viru
entri
fig
like
b
cell
becom
antigenspecif
memori
b
cell
capabl
activ
boost
immun
stimul
factor
induc
rapid
recal
antibodi
respons
outcom
extens
studi
merscovdirect
vaccin
immun
mer
vaccin
could
induc
antigenspecif
cell
immun
respons
well
cell
activ
secret
includ
andor
cytokin
turn
promot
cytotox
cell
lymphocyt
cell
kill
target
cell
infect
merscov
fig
howev
anim
model
neutral
antibodi
alon
abl
protect
challeng
merscov
therefor
cellmedi
cellular
immun
respons
need
may
play
supplementari
role
prevent
merscov
infect
ideal
mer
vaccin
candid
high
immunogen
strong
potenc
judg
abil
induc
potent
immun
respons
neutral
antibodi
well
complet
protect
merscov
infect
lowest
dosag
least
inject
time
appropri
rout
addit
mer
vaccin
need
maintain
good
safeti
without
induc
virusenhanc
antibodi
harm
immun
respons
caus
immunopatholog
effect
mer
vaccin
need
evalu
appropri
anim
model
proceed
human
clinic
trial
substanti
progress
made
develop
mer
anim
model
includ
nonhuman
primat
nhp
rhesu
macaqu
common
marmoset
well
small
anim
model
transgen
tg
mice
tabl
summar
current
avail
anim
model
characterist
potenti
applic
evalu
efficaci
mer
vaccin
nhp
model
initi
establish
effect
vehicl
merscov
infect
vaccin
evalu
rhesu
macaqu
infect
merscov
develop
lower
respiratori
tract
symptom
mildtomoder
interstiti
pneumonia
viru
replic
mainli
occur
alveolar
pneumocyt
also
clinic
sign
diseas
neutral
antibodi
produc
anim
upon
viru
infect
contrast
marmoset
new
merscov
infect
model
develop
much
sever
diseas
progress
sever
pneumonia
lead
signific
viral
replic
lung
partial
lethal
howev
report
demonstr
mildtomoder
nonleth
respiratori
diseas
common
marmoset
limit
addit
clinic
sign
upon
inocul
merscov
except
nhp
camel
infect
merscov
may
present
upper
respiratori
tract
symptom
viru
replic
shed
upper
respiratori
tract
inocul
dromedari
camel
unlik
sarscov
easili
infect
commonli
use
laboratori
anim
includ
syrian
hamster
ferret
mice
merscov
normal
infect
anim
speci
differ
bind
viral
receptor
recent
number
small
anim
model
develop
merscov
exampl
prior
transduct
adenoviru
express
human
mice
becam
sensit
merscov
infect
develop
pneumonia
accompani
clinic
diseas
histopatholog
chang
lung
addit
human
mous
model
establish
mous
replac
human
particular
human
transgen
mous
model
global
express
receptor
fulli
permiss
merscov
infect
infect
anim
develop
progress
pneumonia
demonstr
signific
weight
loss
death
upon
viru
infect
viru
replic
detect
lung
brain
thu
small
anim
model
provid
econom
readili
avail
method
test
efficaci
merscov
candid
vaccin
vaccin
merscov
current
avail
human
use
nevertheless
progress
made
sinc
emerg
merscov
number
mer
vaccin
develop
test
preclin
stage
two
schedul
human
clinic
trial
vaccin
base
recombin
viru
viral
vector
includ
modifi
vaccinia
viru
ankara
mva
adenoviru
ad
measl
viru
mv
nanoparticl
dna
dnaprotein
well
subunit
vaccin
tabl
summar
current
mer
vaccin
develop
unlik
sar
vaccin
usual
develop
base
attenu
inactiv
sarscov
thu
potenti
recov
virul
merscov
vaccin
could
construct
base
recombin
virus
use
revers
genet
accordingli
recombin
merscov
expect
marker
mutat
gener
use
panel
contigu
cdna
span
entir
viral
genom
replic
high
titer
broad
tissu
tropism
also
engin
mutant
merscov
lack
structur
e
protein
rescu
propag
cell
express
viral
e
protein
tran
use
revers
genet
possibl
develop
replicationcompet
propagationdefect
merscov
candid
vaccin
provid
platform
design
live
attenu
merscov
vaccin
sinc
recombin
mer
virus
still
contain
major
viru
compon
safeti
need
test
extens
immunogen
requir
evalu
appropri
anim
model
similar
viral
vectorbas
sar
vaccin
mer
vaccin
also
construct
use
viral
vector
express
major
merscov
protein
normal
protein
sever
mer
vaccin
candid
develop
andor
test
efficaci
mous
model
camel
vector
express
fulllength
protein
merscov
induc
sspecif
antibodi
respons
andor
tcell
respons
mous
model
via
intramuscular
im
intragastr
rout
effect
neutral
merscov
infect
vitro
also
im
subcutan
sc
vaccin
mice
mvabas
fulllength
vaccin
elicit
merscovspecif
cell
respons
neutral
antibodi
protect
mice
merscov
challeng
intranas
intramuscularli
administ
mva
vaccin
induc
mucos
immun
particularli
neutral
antibodi
dromedari
camel
result
signific
reduct
excret
infecti
viru
viral
rna
transcript
merscov
challeng
similarli
recombin
mvbase
mer
vaccin
express
fulllength
truncat
protein
merscov
induc
robust
merscov
neutral
antibodi
cell
respons
protect
mice
transduc
merscov
challeng
although
abl
elicit
strong
immun
respons
andor
protect
viral
vectorbas
vaccin
might
unwant
limit
term
safeti
potenc
exampl
preexist
immun
ad
gener
human
popul
may
caus
advers
effect
induct
vaccin
antigenspecif
immun
respons
thu
reduc
overal
efficaci
vaccin
type
addit
product
neutral
antibodi
viral
vector
demonstr
mv
mvasbas
mer
vaccin
furthermor
fulllength
protein
sarscov
encod
vector
also
induc
nonneutr
antibodi
may
mediat
enhanc
viru
infect
caus
harm
immun
respons
inflamm
enhanc
hepat
special
attent
drawn
develop
merscov
fulllength
proteinbas
viral
vector
vaccin
nanoparticl
use
deliveri
vehicl
develop
mer
vaccin
nanoparticl
contain
merscov
fulllength
protein
prepar
purifi
pellet
infect
baculoviru
insect
cell
absenc
adjuv
nanoparticl
induc
lower
level
merscov
neutral
antibodi
mice
presenc
adjuv
aluminum
hydroxid
alum
matrix
neutral
antibodi
significantli
increas
maintain
also
matrix
significantli
promot
product
neutral
antibodi
compar
alum
thu
adjuv
requir
mer
nanoparticl
vaccin
differ
adjuv
function
differ
promot
immunogen
vaccin
thu
far
efficaci
protect
evalu
vaccin
type
merscov
challeng
model
like
fulllength
gene
sarscov
dna
encod
fulllength
protein
merscov
also
util
develop
mer
vaccin
inde
imelectropor
mice
rhesu
macaqu
synthet
dna
encod
fulllength
protein
merscov
elicit
potent
virusneutr
antibodi
cellular
immun
respons
repres
secret
andor
cytokin
andor
cell
well
product
neutral
antibodi
immun
camel
addit
immun
nhp
protect
merscov
challeng
without
demonstr
clinic
radiograph
sign
pneumonia
sinc
dna
vaccin
encod
merscov
fulllength
protein
potenti
induct
virusenhanc
antibodi
harm
immun
respons
possibl
addit
dnaalon
vaccin
strategi
dna
prime
follow
protein
boost
could
use
develop
mer
vaccin
result
expand
immunogen
efficaci
gener
dna
combin
vaccin
strategi
dna
construct
encod
fulllength
protein
merscov
protein
express
viral
subunit
result
demonstr
imelectropor
prime
fulllength
dna
im
boost
protein
merscov
ribi
alum
aluminum
phosphat
alpo
adjuv
mice
rhesu
macaqu
respect
induc
robust
neutral
antibodi
merscov
infect
confer
protect
nhp
merscovinduc
radiograph
pneumonia
howev
contain
fulllength
dna
vaccin
regimen
potenti
vaccinecaus
immunopatholog
need
investig
proteinbas
subunit
vaccin
merscov
develop
subunit
vaccin
design
basi
fulllength
protein
major
base
viral
rbd
rbdbase
vaccin
evalu
immunogen
protect
immun
number
merscov
anim
model
includ
mice
well
nhp
antigen
function
rbd
protein
also
extens
investig
gener
subunit
vaccin
might
induc
immun
respons
strong
induc
vaccin
type
mention
howev
immunogen
subunit
vaccin
could
significantli
promot
presenc
ideal
adjuv
via
appropri
rout
addit
also
essenti
maintain
suitabl
conform
protein
antigen
vaccin
merscov
rbd
protein
exampl
sc
immun
merscov
rbd
protein
adjuv
montanid
poli
c
induc
longterm
high
titer
sspecif
system
igg
iga
mucos
siga
antibodi
potent
neutral
merscov
infect
compar
sever
differ
rbd
fragment
merscov
protein
fragment
contain
residu
rbd
elicit
highest
neutral
antibodi
mice
rabbit
therefor
identifi
critic
neutral
domain
moreov
sinc
adjuv
improv
abil
rbd
protein
elicit
highest
titer
neutral
antibodi
adjuv
test
consid
ideal
adjuv
use
rbd
subunit
vaccin
even
low
dose
rbd
antigen
plu
adjuv
elicit
suffici
neutral
antibodi
merscov
infect
presenc
adjuv
rbd
protein
protect
mice
merscov
challeng
clearli
identifi
critic
neutral
domain
merscov
rbd
protein
maintain
good
conform
structur
strong
antigen
bind
specif
merscov
rbdspecif
sera
neutral
monoclon
antibodi
well
intact
function
interact
solubl
cellassoci
receptor
term
safeti
consider
subunit
vaccin
account
safest
vaccin
type
contain
viral
genet
materi
includ
essenti
antigen
elicit
protect
immun
respons
thu
exclud
possibl
recov
virul
induc
advers
reaction
differ
vaccin
base
fulllength
protein
rbdbase
mer
subunit
vaccin
contain
major
neutral
epitop
lack
nonneutr
immunodomin
domain
thu
minimum
risk
induc
nonneutr
antibodi
potenti
caus
harm
immun
respons
enhanc
viru
infect
merscov
newli
emerg
infecti
coronaviru
new
categori
c
prioriti
pathogen
caus
high
mortal
human
thu
pose
continu
threat
public
health
global
safeti
sinc
emerg
merscov
tremend
progress
made
develop
mer
vaccin
evalu
efficaci
suitabl
anim
model
present
mer
vaccin
avail
human
use
review
explain
immun
respons
result
merscov
infect
describ
mer
vaccin
criteria
present
avail
small
anim
model
evalu
efficaci
mer
vaccin
current
advanc
vaccin
develop
summar
focus
specif
applic
limit
vaccin
categori
mer
vaccin
categor
recombin
viru
viral
vector
nanoparticl
dna
dnasprotein
subunit
vaccin
denot
specif
applic
limit
categori
taken
togeth
review
provid
valuabl
guidelin
toward
develop
effect
safe
mer
vaccin
base
limit
vaccin
candid
discuss
might
fruit
establish
standard
measur
specif
role
humor
cellular
immun
respons
rel
protect
merscov
infect
evalu
efficaci
correl
immunogen
protect
addit
efficaci
safeti
import
issu
mer
vaccin
experi
garner
sar
vaccin
studi
demonstr
vaccin
base
fulllength
protein
sarscov
may
induc
nonneutr
antibodi
enhanc
effect
viru
infect
harm
immun
respons
caus
immunopatholog
effect
inflamm
increas
sever
thu
develop
mer
vaccin
base
fulllength
protein
precaut
taken
induct
harm
immun
respons
andor
virusenhanc
antibodi
potenti
result
nonneutr
epitop
immunodomin
domain
concomitantli
immunopatholog
effect
mer
vaccin
investig
safeti
test
toxic
experi
also
recommend
move
mer
vaccin
candid
human
clinic
trial
patient
use
one
may
argu
virusenhanc
antibodi
induc
fulllength
protein
merscov
report
far
inde
report
antibodymedi
enhanc
sarscov
infect
year
sinc
viru
first
identifi
guangdong
provinc
china
howev
jaum
et
al
report
sar
vaccin
base
fulllength
protein
could
induc
mice
virusneutr
antibodi
test
vero
cell
cultur
virusenhanc
antibodi
via
manner
detect
cultur
raji
daudi
cell
express
find
suggest
virusenhanc
antibodi
induc
fulllength
protein
merscov
may
detect
appropri
assay
system
use
therefor
would
especi
import
investig
potenti
mer
vaccin
induc
virusenhanc
antibodi
harm
immun
respons
caus
immunopatholog
effect
move
mer
vaccin
candid
human
clinic
trial
lesson
learn
develop
sar
vaccin
shift
develop
vaccin
base
fulllength
protein
begin
develop
rbdbase
vaccin
end
differ
fulllength
protein
rbd
merscov
protein
contain
critic
neutral
domain
lack
immunodomin
domain
nonneutr
epitop
thu
safe
highli
immunogen
induc
potent
neutral
antibodi
protect
immun
merscov
infect
comparison
vaccin
categori
recombin
virus
viral
vector
vaccin
subunit
vaccin
includ
base
rbd
maintain
higher
safeti
profil
due
absenc
viral
genet
materi
infecti
virus
major
conform
neutral
epitop
merscov
rbd
may
attribut
rbd
abil
induc
neutral
antibodi
wildtyp
mutant
viral
strain
sinc
viral
strain
mutat
one
epitop
may
still
sensit
neutral
antibodi
induc
epitop
rbd
demonstr
rbd
capac
elicit
broadspectrum
neutral
antibodi
crossprotect
immun
therefor
similar
rbdbase
sar
vaccin
subunit
vaccin
base
merscov
rbd
greatest
potenti
develop
effect
safe
vaccin
candid
note
addit
rbd
region
ntermin
domain
fragment
merscov
may
also
possess
neutral
epitop
thu
combin
rbd
ntermin
domain
subunit
vaccin
may
result
synergist
effect
induc
broadli
crossneutr
antibodi
diverg
merscov
strain
present
two
fulllength
merscov
candid
vaccin
one
base
mva
dna
schedul
clinic
trial
continu
increas
extens
research
promis
mer
vaccin
preclin
studi
candid
high
efficaci
strong
safeti
push
forward
clinic
trial
prevent
merscov
infect
next
five
year
robust
afford
small
anim
model
develop
help
evalu
efficaci
mer
vaccin
comprehens
studi
efficaci
safeti
mer
vaccin
expect
sinc
merscov
rbdbase
subunit
vaccin
induc
strong
immun
respons
neutral
antibodi
maintain
highest
safeti
profil
vaccin
expect
increas
number
invest
govern
big
pharma
expect
vaccin
brought
clinic
trial
expediti
manner
upon
approv
use
prevent
merscov
infect
human
build
biodef
stockpil
merscov
use
bat
dromedari
camel
like
natur
reservoir
intermedi
transmiss
host
humantohuman
transmiss
confirm
therefor
newli
ad
categori
c
prioriti
pathogen
merscov
pose
threat
public
health
global
safeti
highlight
import
develop
effect
safe
mer
vaccin
among
four
major
structur
protein
merscov
spike
protein
import
viral
pathogenesi
merscov
depend
protein
subunit
bind
cellular
receptor
dipeptidyl
peptidas
receptorbind
domain
rbd
follow
mediat
merscov
entri
target
cell
viral
protein
rbd
major
vaccin
target
similar
merscov
infect
mer
vaccin
trigger
antigenspecif
humor
mucos
andor
cellular
immun
respons
cellular
immun
respons
might
requir
clear
kill
viru
humor
immun
respons
particularli
neutral
antibodi
play
critic
role
protect
merscov
infect
sever
anim
model
includ
small
anim
model
express
receptor
develop
evalu
efficaci
mer
vaccin
mer
vaccin
avail
human
use
mer
vaccin
develop
preclin
stage
schedul
human
clinic
trial
vaccin
categor
recombin
viru
viral
vector
nanoparticl
dna
dnasprotein
subunit
vaccin
major
base
viral
protein
addit
major
neutral
epitop
rbd
fulllength
protein
also
contain
immunodomin
domain
nonneutr
epitop
induc
nonneutr
antibodi
may
mediat
enhanc
viral
infect
harm
immun
respons
caus
immunopatholog
effect
induc
fulllength
protein
sarscov
rbd
subunit
merscov
protein
contain
major
neutral
epitop
lack
immunodomin
domain
nonneutr
epitop
thu
much
less
risk
induc
virusenhanc
antibodi
harm
immun
respons
better
potenti
fulllength
protein
develop
effect
safe
mer
vaccin
